Moreover, in NASH biopsies, PNPLA3 variant carriers showed higher degree of steatosis (p = 0.025), portal inflammation (p = 0.034), DR (p = 0.036), EpCAM+ hepatocytes (p = 0.029), and higher number of αSMA+ portal/septal MFs (p = 0.011) when compared with WT patients (Supplementary Table 2). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.